-

Seventy-Four Percent of Pharmaceutical Marketing Executives Say Changes in Third-Party Cookie Management Will Be Impactful or Very Impactful on Their Media Plans

Yet Over-reliance on Agencies for a Path Forward Could Lead to Unrealistic or Ineffective Strategies

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest TGaS Advisors’ brief entitled Changes in Third-Party Cookie Management and Their Effects on Pharmaceutical Brands. The paper finds that although most respondents did not have a clear understanding of the changes in third-party cookie management, 74 percent of pharma marketing executives say the changes will be impactful or very impactful on their media plans. However, less than half of those companies have taken action to address the coming changes.

Pharmaceutical executives will rely heavily on their media agencies to understand the intricacies of the changes and recommend strategies to minimize the impact these changes may have on digital marketing. Forty-two percent of respondents indicate that their agency is responsible for understanding the effect of eliminating third-party cookies and mitigating any impact.

“Our research shows a possible over-reliance on agencies to address the challenges created by elimination of third-party cookies,” said Scott Szewczak, Senior Service Director, Omnichannel Marketing, TGaS Advisors, a division of Trinity Life Sciences. “Media agency partnerships will be critical. Changes to data collection and tagging, and integration with external partners require deep understanding and engagement from internal centers of excellence.”

The white paper outlines the mitigation strategies that marketing departments within pharma are currently exploring, alternative plans and additional strategies for the industry to consider. Changes in Third-Party Cookie Management and Their Effects on Pharmaceutical Brands is currently available.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Trinity Life Sciences


Release Summary
Seventy-four percent of pharmaceutical marketing executives say changes in third-party cookie management will be impactful on their media plans.
Release Versions

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

More News From Trinity Life Sciences

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors. Over her distinguished tenure, Ms. Orne helped guide Trinity’s evo...

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies. The report ranks each b...

Trinity Expands Global Footprint with Acquisition of EVERSANA’s APACME Advisory Services

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization solutions and recognized for being a strategic, tech-enabled commercialization company that empowers pharma, biotech, and medtech organizations to advance medical innovations, announced today the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME). The strategic acquisition will transition EVERSANA’s advisory services operation in APACME to Trinity, further...
Back to Newsroom